XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis

Jerry Y. Tan Chun Bing, Andrew A. Yacat, Dennis L. Sacdalan
2015 Acta medica Philippina  
doi:10.47895/amp.v49i2.988 fatcat:u2bkfmpa2bbqfewvfgysgt75xa